Your browser doesn't support javascript.
loading
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont, Alexander M M; Blank, Christian U; Mandala, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Di Giacomo, Anna Maria; van den Eertwegh, Alfonsus J M; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; Lorigan, Paul C; van Akkooi, Alexander C J; Krepler, Clemens; Ibrahim, Nageatte; Marreaud, Sandrine; Kicinski, Michal; Suciu, Stefan; Robert, Caroline.
Afiliação
  • Eggermont AMM; Princess Máxima Center, Utrecht, the Netherlands.
  • Blank CU; Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
  • Mandala M; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
  • Long GV; Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia.
  • Atkinson VG; Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • Dalle S; Hospices Civils de Lyon Cancer Institute, Lyon, France.
  • Haydon AM; Alfred Hospital, Melbourne, Victoria, Australia.
  • Meshcheryakov A; N.N. Blokhin Cancer Research Center, Moscow, Russian Federation.
  • Khattak A; Fiona Stanley Hospital and Edith Cowan University, Perth, Western Australia, Australia.
  • Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, New South Wales, Australia.
  • Sandhu S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Larkin J; Royal Marsden Hospital, London, United Kingdom.
  • Puig S; Hospital Clinic Universitari de Barcelona, Barcelona, Spain.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
  • Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Schadendorf D; University Hospital Essen, Essen, Germany.
  • Koornstra R; German Cancer Consortium, Heidelberg, Germany.
  • Hernandez-Aya L; Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
  • Di Giacomo AM; Washington University School of Medicine, St Louis, MO.
  • van den Eertwegh AJM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
  • Grob JJ; Amsterdam University Medical Center, location VUMC, Amsterdam, the Netherlands.
  • Gutzmer R; Aix Marseille University, Hôpital de la Timone, Marseille, France.
  • Jamal R; Skin Cancer Center, Hannover Medical School, Hanover, Germany.
  • Lorigan PC; Centre Hospitalier de l'Université de Montréal (CHUM), Centre de recherche du CHUM, Montreal, Quebec, Canada.
  • van Akkooi ACJ; Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Krepler C; Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
  • Ibrahim N; Merck & Co, Kenilworth, NJ.
  • Marreaud S; Merck & Co, Kenilworth, NJ.
  • Kicinski M; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Suciu S; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Robert C; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
J Clin Oncol ; 38(33): 3925-3936, 2020 11 20.
Article em En | MEDLINE | ID: mdl-32946353
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_malignant_skin_melanoma / 6_skin_diseases Assunto principal: Neoplasias Cutâneas / Anticorpos Monoclonais Humanizados / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_malignant_skin_melanoma / 6_skin_diseases Assunto principal: Neoplasias Cutâneas / Anticorpos Monoclonais Humanizados / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda